← Back|DXCMDexCom, Inc.
70.93 USD-0.7%Healthcare
About the company

DexCom makes continuous glucose monitoring devices used by people with diabetes to track their blood sugar levels in real time, without requiring the frequent finger-prick blood tests that older glucose monitoring methods required. Its sensors are worn on the body and continuously transmit glucose readings to a smartphone app or dedicated receiver, giving patients and their doctors ongoing visibility into blood sugar trends rather than isolated point-in-time readings. Continuous glucose monitoring has become an increasingly standard part of diabetes management, particularly for people with Type 1 diabetes and those with Type 2 diabetes who use insulin, replacing older testing methods for a growing share of the diabetic population. DexCom's revenue model includes recurring sales of the sensors that need periodic replacement, giving it a razor-and-blades style revenue stream layered on top of initial device sales, with growth tied to both new patient adoption and broader recognition of continuous monitoring as standard diabetes care.

Overall
5.7
Market Cap
$27.4B
P/E (ttm)
30.4
Analyst Target
85.75 USD
+20.9%
Data as of 04:26 ·